Notification of Preliminary Results

RNS Number : 5796X

Evgen Pharma PLC

09 May 2016

 

For immediate release

9 May 2016

 

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")

Notification of Preliminary Results

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its preliminary results for the year ended 31 March 2016 on Tuesday 31 May 2016.

A meeting for analysts will be held at 10.00am on the morning of the results announcement at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. For further information, or to register attendance, please contact Buchanan at the contact details below.

Enquiries:

Evgen Pharma plc                                            Dr Stephen Franklin, CEO www.evgen.com	c/o [phone]
Buchanan                                            Mark Court, Sophie Cowles, Stephanie Watson [e-mail]	[phone]
Northland Capital Partners Limited Matthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance) John Howes, Mark Treharne (Corporate Broking)	[phone]

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. For further information please visit www.evgen.com

 

END

 

 

NORUWURRNAAVRUR